Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biofrontera (BFRI) Share-based Compensation (2021 - 2025)

Biofrontera (BFRI) has 5 years of Share-based Compensation data on record, last reported at $236000.0 in Q3 2025.

  • For Q3 2025, Share-based Compensation fell 18.06% year-over-year to $236000.0; the TTM value through Sep 2025 reached $961000.0, up 1.37%, while the annual FY2024 figure was $1.0 million, 2.49% down from the prior year.
  • Share-based Compensation reached $236000.0 in Q3 2025 per BFRI's latest filing, up from $187000.0 in the prior quarter.
  • Across five years, Share-based Compensation topped out at $551000.0 in Q2 2022 and bottomed at $129000.0 in Q4 2021.
  • Average Share-based Compensation over 5 years is $294187.5, with a median of $249000.0 recorded in 2023.
  • Peak YoY movement for Share-based Compensation: skyrocketed 196.9% in 2022, then crashed 52.99% in 2023.
  • A 5-year view of Share-based Compensation shows it stood at $129000.0 in 2021, then surged by 196.9% to $383000.0 in 2022, then plummeted by 40.47% to $228000.0 in 2023, then soared by 31.14% to $299000.0 in 2024, then decreased by 21.07% to $236000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $236000.0 in Q3 2025, $187000.0 in Q2 2025, and $239000.0 in Q1 2025.